Muscle

Muscle Wasting Disease (MWD) in Cachexia and Sarcopenia

Muscle Structure and Function Recovery: Adalimumab-Calcium Channel Synergy in Post-Ischemic Stroke Sarcopenia.

<p><b>BACKGROUND</b></p><p>Adalimumab, a TNF-ฮฑ inhibitor, is widely used clinically. Recent studies suggest Adalimumab can improve muscle damage after ischemic stroke (IS), but its protective mechanisms remain unclear. This study investigates the effect of adalimumab on muscle structure post-IS and the role...

๐Ÿ—“๏ธ 2025-11-10
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreMuscle Structure and Function Recovery: Adalimumab-Calcium Channel Synergy in Post-Ischemic Stroke Sarcopenia.

Targeting Progesterone Receptor Membrane Component 1 to Improve Muscle Development and Glucose Homeostasis.

<p><b>BACKGROUND</b></p><p>Type 2 diabetes mellitus (T2D) arises from the interplay between peripheral insulin resistance and pancreatic ฮฒ-cell dysfunction, ultimately leading to impaired glucose utilization and chronic hyperglycemia. Despite therapeutic advances, the multifactorial nature of T2D continues to demand the development of...

๐Ÿ—“๏ธ 2025-11-10
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreTargeting Progesterone Receptor Membrane Component 1 to Improve Muscle Development and Glucose Homeostasis.

Rethinking Muscle Aging Through the Lens of Fibro-Adipogenic Progenitors.

Aging of skeletal muscles is accompanied by a progressive deposition of adipose and fibrotic tissue within the interstitial compartment. This process profoundly disrupts the structural integrity and contractile function of the muscle. Such maladaptive remodeling not only compromises muscle performance...

๐Ÿ—“๏ธ 2025-11-10
๐Ÿ“ฐ Publication: Aging And Disease
Read MoreRethinking Muscle Aging Through the Lens of Fibro-Adipogenic Progenitors.

An Isogenic Human Myoblast Cell Model for Cystinosis Myopathy Reveals Alteration of Key Myogenic Regulatory Proteins.

<p><b>BACKGROUND</b></p><p>Cystinosis is a rare multisystem, autosomal recessive disease caused by dysfunction or loss of cystinosin (CTNS), which results in lysosomal cystine accumulation, primarily affecting the kidneys. Advances in renal transplantation, cysteamine treatment and improved medical care have increased life expectancy,...

๐Ÿ—“๏ธ 2025-11-10
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreAn Isogenic Human Myoblast Cell Model for Cystinosis Myopathy Reveals Alteration of Key Myogenic Regulatory Proteins.

Sarcopenia in Atrial Fibrillation: A Risk Factor for Adverse Outcomes in a UK Biobank Study.

<p><b>BACKGROUND AND AIMS</b></p><p>Sarcopenia, characterized by reduced muscle mass and function, has been increasingly implicated in cardiovascular disorders. However, its prognostic relevance in atrial fibrillation (AF) remains unclear. This study evaluated the association between sarcopenia and adverse outcomes in individuals with...

๐Ÿ—“๏ธ 2025-11-09
๐Ÿ“ฐ Publication: Europace
Read MoreSarcopenia in Atrial Fibrillation: A Risk Factor for Adverse Outcomes in a UK Biobank Study.

Budget impact analysis of a muscle-targeted nutritional intervention for sarcopenia.

<p><b>BACKGROUND</b></p><p>In old adult patients with sarcopenia hospitalized for rehabilitation, the superior clinical benefit of a muscle-targeted formula (MTF; whey protein-based enriched with leucine and vitamin D) over an iso-caloric protein-free one was assessed through the IRIS trial (NCT03120026). The aim...

๐Ÿ—“๏ธ 2025-11-09
๐Ÿ“ฐ Publication: Clinical Nutrition
Read MoreBudget impact analysis of a muscle-targeted nutritional intervention for sarcopenia.

Anabolic Effects of Salbutamol Are Lost Upon Immobilization.

<p><b>BACKGROUND</b></p><p>Periods of muscle disuse occur during hospitalization, illness or the recovery from (sports) injury and lead to a rapid loss of muscle mass and the development of insulin resistance. Salbutamol is a fast-acting ฮฒ2-adrenoreceptor agonist that may improve muscle protein...

๐Ÿ—“๏ธ 2025-11-06
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreAnabolic Effects of Salbutamol Are Lost Upon Immobilization.

Sarcopenia and MASLD: novel insights and the future.

Metabolic dysfunction-associated steatotic liver disease (MASLD; previously known as non-alcoholic fatty liver disease) is the leading cause of chronic liver disease worldwide and is closely linked to the obesity epidemic. MASLD often coexists with sarcopenia, an age-related loss of muscle...

๐Ÿ—“๏ธ 2025-11-06
๐Ÿ“ฐ Publication: Nature Reviews Endocrinology
Read MoreSarcopenia and MASLD: novel insights and the future.

EyaHOST, a modular genetic system for investigation of intercellular and tumor-host interactions in Drosophila melanogaster.

Studying intercellular and interorgan interactions in animal models is key to understanding development, physiology, and disease. We introduce EyaHOST, a system for clonal combinatorial loss- and gain-of-function genetics in fluorescently labeled cells under QF2-QUAS eya promoter control. Distinct from mosaic...

๐Ÿ—“๏ธ 2025-11-06
Read MoreEyaHOST, a modular genetic system for investigation of intercellular and tumor-host interactions in Drosophila melanogaster.

Glucagon-like peptide-1 receptor agonists and sarcopenia-related markers in diabetes: A systematic review and meta-analysis.

<p><b>AIMS</b></p><p>GLP-1 receptor agonists (GLP-1RAs) are first-line therapies for type 2 diabetes (T2DM) due to their additional weight-lowering and cardiovascular benefits. However, their impact on muscle mass is debated, posing a concern for sarcopenia in older adults with T2DM. This systematic...

๐Ÿ—“๏ธ 2025-11-05
๐Ÿ“ฐ Publication: Clinical Nutrition
Read MoreGlucagon-like peptide-1 receptor agonists and sarcopenia-related markers in diabetes: A systematic review and meta-analysis.

A focus shift from sarcopenia to muscle health in the Asian Working Group for Sarcopenia 2025 Consensus Update.

The Asian Working Group for Sarcopenia (AWGS) presents an updated 2025 consensus reframing sarcopenia management through a life-course approach to muscle health promotion. While aligning with the Global Leadership Initiative in Sarcopenia (GLIS), this update provides healthcare providers with Asia-specific...

๐Ÿ—“๏ธ 2025-11-05
Read MoreA focus shift from sarcopenia to muscle health in the Asian Working Group for Sarcopenia 2025 Consensus Update.

Effect of Skeletal Muscle Mass and Its Associated Mediators on the Development of Steatotic Liver Disease: A Cohort Study in China.

<p><b>BACKGROUND</b></p><p>Understanding the relationship between relative skeletal muscle mass and newly proposed steatotic liver disease (SLD) is crucial, but research gaps still exist. Based on a cohort study, we investigated the impact of relative skeletal muscle mass on incident SLD and...

๐Ÿ—“๏ธ 2025-11-04
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreEffect of Skeletal Muscle Mass and Its Associated Mediators on the Development of Steatotic Liver Disease: A Cohort Study in China.

Changes in Lean Muscle Mass, Muscle Strength, and Physical Performance Following First-Line Chemotherapy in Patients With Lymphoma.

Lymphomas are common cancers affecting the lymphatic system. Chemotherapy is a standard treatment, yet its impact on patient's physical capacity remains understudied. This study aimed to evaluate changes in body composition, muscle strength, and physical performance in patients diagnosed with...

๐Ÿ—“๏ธ 2025-11-04
๐Ÿ“ฐ Publication: Hematological Oncology
Read MoreChanges in Lean Muscle Mass, Muscle Strength, and Physical Performance Following First-Line Chemotherapy in Patients With Lymphoma.

Therapeutic potential of FGF19 in combatting osteosarcopenia: effects on muscle strength and bone health in aged male mice.

Osteosarcopenia, characterized by the coexistence of osteopenia/osteoporosis and sarcopenia, represents a significant health concern in geriatrics, with an increased risk of falls and fractures. The enterokine fibroblast growth factor 19 (FGF19) was recently shown to prevent muscle weakness in preclinical...

๐Ÿ—“๏ธ 2025-11-04
Read MoreTherapeutic potential of FGF19 in combatting osteosarcopenia: effects on muscle strength and bone health in aged male mice.

The mitochondrial-targeted antioxidant SkQ1 prevents skeletal muscle mitochondrial-apoptotic but not necroptotic signalling during ovarian cancer.

The degree to which mitochondrial-linked programmed cell death pathways contribute to skeletal muscle atrophy during cancer remains unknown. Here we combined a novel and robust mouse model of metastatic ovarian cancer with chronic administration of the mitochondrial-targeted antioxidant SkQ1 to...

๐Ÿ—“๏ธ 2025-11-03
๐Ÿ“ฐ Publication: Journal Of Physiology-London
Read MoreThe mitochondrial-targeted antioxidant SkQ1 prevents skeletal muscle mitochondrial-apoptotic but not necroptotic signalling during ovarian cancer.

Muscle Wasting Disease (MWD) in Cachexia and Sarcopenia

Weight loss is the hallmark of any progressive acute or chronic disease state. In its extreme form, it involves a significant lean body mass (including skeletal muscle), and fat loss. Skeletal muscle provides a fundamental basis for human function, enabling locomotion and respiration. Muscle wasting is related to a poor quality of life and increased morbidity/ mortality.

Two common but distinct conditions characterized by a loss of skeletal muscle mass are sarcopenia and cachexia. Sarcopenia, cachexia, and anorexic disorders (protein-energy malnutrition) represent the major causes of muscle-wasting disorders.

It has been known for millennia that muscle and fat wasting leads to poor outcomes including deaths in chronic disease states.

It is usually accompanied by physical inactivity, decreased mobility, slow gait, and poor physical endurance which are also common features of the frailty syndrome.

Fig. 1 โ€“ Framework for the suggested classification of MWD by disease etiology and disease progression.

Both cachexia and sarcopenia are characterized by an important muscle dysfunction that leads to increased morbidity and mortality.

Fig. 2 โ€“ The cachexia/ sarcopenia pyramid. Both lead to muscle dysfunction.

References

Kalantar-Zadeh K, Rhee C, Sim JJ, Stenvinkel P, Anker SD, Kovesdy CP.ย Why cachexia kills: examining the causality of poor outcomes in wasting conditions.ย J Cachexia Sarcopenia Muscle 2013; 4: 89โ€“94.

Evans WJ, Morley JE, Argilรฉs J, Bales C, Baracos V, Guttridge D, et al.ย Cachexia: a new definition.ย Clin Nutr 2008; 27: 793โ€“799.

Anker SD, Coats AJS, Morley JE, Rosano G, Bernabei R, Haehling S, et al.ย Muscle wasting disease: a proposal for a new disease classification.ย J Cachexia Sarcopenia Muscle 2014; 5: 1โ€“3.

Argiles JM, Busquets S, Stemmler B, Lรณpez-Soriano FJ.ย Cachexia and sarcopenia: mechanisms and potential targets for intervention.ย Current Opinion in Pharmacology 2015; 22: 100โ€“106.

Bowen TS, Schuler G, Adams V.ย Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training.ย J Cachexia Sarcopenia Muscle 2015; 6: 197โ€“207.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!